PCRX Stock — Pacira BioSciences Inc.: Cash, EV, Pipeline

Share price

$24.69

Market cap

$984.2M

Cash

$251.0M

Enterprise value

$1,096.3M

Balance sheet

Cash	$251.0M
Debt	$363.1M
Net cash	-$112.1M
Enterprise value	$1,096.3M
Basic shares	39.8M shares
Fully diluted shares	58.3M shares
Fully diluted market cap	$1,439.4M
Cash per share	$6.31

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PCRX daily closes…

Loading price history…

Pipeline assets

EXPAREL (bupivacaine liposome injectable suspension)

Approved · Active Modality: Liposomal injectable suspension (pMVL drug delivery technology)

Partnerships LG Chem (Jan 2026): exclusive rights to commercialize EXPAREL in select Asia-Pacific markets; Pacira manufactures. Marketing authorization filed in South Korea and Thailand.

Indications

Postsurgical local analgesia via infiltration (patients 6+ years) (Approved)
Postsurgical regional analgesia (interscalene brachial plexus block, sciatic nerve block, adductor canal block) (Approved)

Status note Commercialized in the US since Apr 2012; approved in select European countries and the UK (Nov 2021). Pediatric study commitments ongoing; FDA/EMA waived pediatric requirements for nerve-block indications.

ZILRETTA (triamcinolone acetonide extended-release injectable suspension)

Approved · Active Modality: Extended-release injectable suspension (intra-articular)

Partnerships J&J MedTech (Jul 2025): exclusive third-party co-promoter for ZILRETTA in the US (initial term through 2031); Johnson & Johnson MedTech sales force extends reach beyond orthopedics. Acquired via Flexion Therapeutics (Nov 2021; contingent milestones through Dec 2030)

Indications

Osteoarthritis knee pain (Approved)

Status note First and only extended-release intra-articular injection indicated for OA knee pain.

PCRX-201

Phase 2 · Active Modality: Gene therapy (HCAd vector)

Aliases enekinragene inzadenovec

Target IL-1Ra (interleukin-1 receptor antagonist)

Partnerships Baylor College of Medicine: exclusive worldwide license to underlying PCRX-201 patents. Acquired via Flexion (Nov 2021); company holds a stake in GQ Bio (HCAd platform).

Indications

Osteoarthritis knee pain (Phase 2)

Status note Locally administered gene therapy for OA knee pain. FDA RMAT designation Feb 2024. Lead program from proprietary high-capacity adenovirus (HCAd) vector platform.

PCRX-2002

Phase 2 · Active Modality: Long-acting formulation

Indications

Postsurgical pain (Phase 2)

Status note Complementary long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06995352	Phase 4	Enrolling by invitation	Collaborator	University of California, San Diego	—	Moderate-to-severely Painful Ankle Surgery	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for University of California, San Diego on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PCRX — Pacira BioSciences Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials